Trabectedin API Product Introduction​

Overview​

Trabectedin, with the CAS number 114899-77-3, is a highly specialized and sought-after active pharmaceutical ingredient (API) revolutionizing the field of oncology. This synthetic compound, renowned for its potent anti-cancer properties, serves as the cornerstone for developing cutting-edge treatments for a variety of malignancies.​

Properties​

Trabectedin API presents as a yellow to orange solid powder, exuding a distinct visual identity. It demonstrates limited solubility in water, but shows better solubility in organic solvents like dimethyl sulfoxide (DMSO) and ethanol. This solubility profile provides flexibility in formulating various pharmaceutical products, enabling manufacturers to create effective dosage forms tailored to diverse clinical needs. The powder is stable under appropriate storage conditions, maintaining its integrity and potency over time, which ensures reliable performance during the manufacturing process and in the final drug products.​

Product Highlights​

1. Unique and Potent Anti-cancer Mechanism​

Trabectedin stands out in the oncology landscape with its novel mode of action. Unlike traditional chemotherapeutic agents, it doesn't merely disrupt cell division but targets the DNA repair mechanisms within cancer cells. By binding to the minor groove of DNA, it forms adducts that interfere with transcription processes and trigger apoptosis, or programmed cell death, in cancer cells. This targeted approach not only effectively eliminates tumor cells but also minimizes damage to healthy cells, reducing the severity of side effects commonly associated with chemotherapy. Its unique mechanism has been proven effective against soft tissue sarcomas and ovarian cancer, offering new hope for patients who may not respond well to conventional treatments. For pharmaceutical companies, leveraging this unique mechanism allows for the development of differentiated and highly effective oncology drugs, providing a competitive edge in the market.​

2. Broad Clinical Application Potential​

While already approved for the treatment of advanced soft tissue sarcoma and ovarian cancer, Trabectedin's potential extends far beyond these indications. Ongoing clinical trials are exploring its efficacy in treating other aggressive cancers such as breast cancer, lung cancer, and pediatric tumors. This wide-ranging clinical applicability positions Trabectedin as a versatile API for pharmaceutical developers. As research progresses and more indications are discovered, drugs formulated with Trabectedin API will have access to larger patient populations, translating into significant market opportunities. For healthcare providers and patients alike, the expanding range of applications means more treatment options and increased chances of finding an effective therapy for challenging cancers.​

3. Superior Safety and Tolerability Profile​

Compared to many other anti-cancer drugs, Trabectedin offers a more favorable safety and tolerability profile. Its targeted action reduces the impact on normal, rapidly dividing cells like those in the bone marrow, hair follicles, and gastrointestinal tract, which are often the source of severe side effects in chemotherapy. This results in fewer occurrences of debilitating symptoms such as neutropenia, alopecia, and severe nausea, allowing patients to maintain a better quality of life during treatment. For pharmaceutical companies, the relatively mild side effect profile makes drugs containing Trabectedin API more appealing to patients and healthcare providers, facilitating market acceptance and potentially leading to increased market share. Additionally, the improved tolerability may enable more consistent treatment regimens, enhancing treatment efficacy and patient outcomes.​

Quality Assurance​

Our Trabectedin API is manufactured in state-of-the-art facilities that adhere strictly to international cGMP standards. Rigorous quality control processes are implemented at every stage of production, from raw material sourcing to final product release. Advanced analytical techniques, including high-performance liquid chromatography (HPLC) and mass spectrometry, are used to ensure the product's purity, potency, and consistency, with a minimum purity level of 98%. Our commitment to quality guarantees that you receive a reliable and high-performing API that meets the most stringent regulatory requirements worldwide.​

Application Areas​

Primarily used in the development and production of oncology drugs for the treatment of soft tissue sarcoma, ovarian cancer, and other cancers under clinical investigation. Ideal for pharmaceutical companies engaged in anti-cancer drug research, development, and manufacturing, as well as contract manufacturing organizations (CMOs) looking to incorporate a high-quality, innovative API into their product portfolio.​

Storage Conditions​

Store the product at 2 - 8°C in a dry, well-ventilated area away from direct light. Keep the container tightly sealed to prevent moisture absorption and contamination, ensuring the long-term stability and integrity of the API.​

If you have any questions or require further information about our Trabectedin API, please do not hesitate to contact us. Our dedicated team of experts is ready to assist you and explore potential collaborations to drive innovation in the field of oncology.